ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,90
-0,60%
Bitcoin
60 162,66
-2,35%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MorphoSys AG (MOR)

  7. MorphoSys AG (MOR) Actualités

MOR

MorphoSys (MOR)

MorphoSys AG
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MOR
DateHeureSourceTitreSymboleSociété
20/06/202408h47Business WireMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority ShareholdersNASDAQ:MORMorphoSys AG
10/06/202417h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MORMorphoSys AG
04/06/202422h06Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:MORMorphoSys AG
29/04/202422h01Business WireMorphoSys AG Reports First Quarter 2024 Financial ResultsNASDAQ:MORMorphoSys AG
11/04/202414h39Business WireMorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisNASDAQ:MORMorphoSys AG
13/03/202421h02Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:MORMorphoSys AG
06/02/202412h14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNASDAQ:MORMorphoSys AG
11/12/202301h31Business WireMorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 StudyNASDAQ:MORMorphoSys AG
20/11/202323h19Dow Jones NewsMorphoSys Trial for Blood-Cancer Treatment Reaches Primary EndpointNASDAQ:MORMorphoSys AG
20/11/202322h30Business WireMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom ReductionNASDAQ:MORMorphoSys AG
15/11/202322h01Business WireMorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial ResultsNASDAQ:MORMorphoSys AG
09/08/202322h01Business WireMorphoSys AG Reports Second Quarter and First Half 2023 Financial ResultsNASDAQ:MORMorphoSys AG
03/05/202322h01Business WireMorphoSys AG Reports First Quarter 2023 Financial ResultsNASDAQ:MORMorphoSys AG
17/04/202313h37Business WireAprès cinq ans, MorphoSys et Incyte annoncent les résultats de l'étude L-MIND montrant des réponses prolongées et durables chez des patients atteints de LDGCB récidivant ou réfractaire traités par Monjuvi® (tafasitamab-cxix)NASDAQ:MORMorphoSys AG
17/04/202313h37Business WireMorphoSys und Incyte präsentieren Fünf-Jahres-Ergebnisse der L-MIND-Studie, die bei Patienten mit rezidiviertem oder refraktärem DLBCL in Behandlung mit Monjuvi® (Tafasitamab-cxix) ein verlängertes, dauerhaftes Ansprechen zeigenNASDAQ:MORMorphoSys AG
16/04/202321h01Business WireMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)NASDAQ:MORMorphoSys AG
15/03/202321h03Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:MORMorphoSys AG
17/11/202222h25TipRanksJMP Securities Sticks to Its Buy Rating for Morphosys Ag (MOR)NASDAQ:MORMorphoSys AG
16/11/202222h01Business WireMorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial ResultsNASDAQ:MORMorphoSys AG
14/11/202211h30Dow Jones NewsMorphoSys Shares Slide After Roche's Alzheimer's Drug Trial FailsNASDAQ:MORMorphoSys AG
11/08/202214h16TipRanksJ.P. Morgan Keeps Their Hold Rating on Morphosys Ag (MOR)NASDAQ:MORMorphoSys AG
04/08/202222h25TipRanksJMP Securities Thinks Morphosys Ag’s Stock is Going to RecoverNASDAQ:MORMorphoSys AG
03/08/202222h01Business WireMorphoSys AG Reports Second Quarter and First Half 2022 Financial ResultsNASDAQ:MORMorphoSys AG
15/06/202214h41PR Newswire (US)I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210NASDAQ:MORMorphoSys AG
14/06/202222h01Business WireMorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210NASDAQ:MORMorphoSys AG
10/06/202209h15Business WireMorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022NASDAQ:MORMorphoSys AG
12/05/202216h45Business WireMorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual MeetingsNASDAQ:MORMorphoSys AG
05/05/202220h55TipRanksMorphosys Ag (MOR) Receives a Buy from JMP SecuritiesNASDAQ:MORMorphoSys AG
04/05/202222h01Business WireMorphoSys AG Reports First Quarter 2022 Financial ResultsNASDAQ:MORMorphoSys AG
16/03/202221h07Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateNASDAQ:MORMorphoSys AG
 Showing the most relevant articles for your search:NASDAQ:MOR

Dernières Valeurs Consultées

NASDAQ
RIOT
Riot Platforms
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés